Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
about
New insights into the use of currently available non-steroidal anti-inflammatory drugsClinical Pharmacology and Cardiovascular Safety of NaproxenEfficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs.Advances in NSAID development: evolution of diclofenac products using pharmaceutical technologyThe effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritisRobenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial.Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dogHuman cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids.Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.Identifying behavioural differences in working donkeys in response to analgesic administration.Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs.Carprofen pharmacokinetics in plasma and in control and inflamed canine tissue fluid using in vivo ultrafiltration.Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts.Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapyInfluence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs
P2860
Q26852330-5F96FBD0-26AE-40D4-B9B8-D8B5D4A9B765Q30360728-1718324E-AA6E-4F63-BF6E-744E1569E49CQ33698477-0C31CF6A-4784-4D8A-84C8-24505674A229Q33836650-EB63021C-88B5-463B-8BC1-ACBCAC6C0D0EQ34475981-52A4436E-A71E-4EFF-9F77-3DE0D259DD4BQ34604437-6BAA7603-BCB9-45FD-B51B-D1B96D5CDB39Q34702739-1846C216-228D-4628-9FC9-D12392C09E20Q35065366-D41A35D0-4561-457D-B840-D28A3205EEE7Q36020274-E4F4BB37-4C56-4628-BF46-B6D2E8F7E80EQ36388949-3E1F2107-06F6-4631-84FB-557453A5AF46Q39200631-297AE161-1AA7-4ACA-B751-DA119EFF1B10Q40155507-1550D350-D389-429B-AAB5-D2ECED2B5E0DQ44857486-AB122395-FE25-42A8-8A97-BD0041DB2EBCQ46055251-7BB2CD59-9BC9-40D3-84E5-09E66B7F57D0Q47142226-9C7C1304-86B4-49F3-9C39-037C4A99EF53Q53598914-DA9F9C3F-9038-4DA2-B45E-77E9251A261FQ58777712-1ED9E99E-9CEB-424E-A47A-91B932B43BC2Q58800798-4C297793-D8BC-4CD4-9D31-B0158A60A23B
P2860
Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combining enzyme specificity a ...... : towards better tolerability?
@ast
Combining enzyme specificity a ...... : towards better tolerability?
@en
type
label
Combining enzyme specificity a ...... : towards better tolerability?
@ast
Combining enzyme specificity a ...... : towards better tolerability?
@en
prefLabel
Combining enzyme specificity a ...... : towards better tolerability?
@ast
Combining enzyme specificity a ...... : towards better tolerability?
@en
P356
P1433
P1476
Combining enzyme specificity a ...... : towards better tolerability?
@en
P2093
P304
P356
10.1093/RHEUMATOLOGY/KEM070
P577
2007-04-25T00:00:00Z